39 results match your criteria: "Seattle Cancer Care Alliance Proton Therapy Center[Affiliation]"
Int J Radiat Oncol Biol Phys
July 2024
Department of Radiation Oncology and Winship Cancer Institute, Emory University, Atlanta, Georgia.
Stereotactic body radiation therapy (SBRT) and hypofractionation using pencil-beam scanning (PBS) proton therapy (PBSPT) is an attractive option for thoracic malignancies. Combining the advantages of target coverage conformity and critical organ sparing from both PBSPT and SBRT, this new delivery technique has great potential to improve the therapeutic ratio, particularly for tumors near critical organs. Safe and effective implementation of PBSPT SBRT/hypofractionation to treat thoracic malignancies is more challenging than the conventionally fractionated PBSPT because of concerns of amplified uncertainties at the larger dose per fraction.
View Article and Find Full Text PDFArXiv
February 2024
Department of Radiation Oncology and Winship Cancer Institute, Emory University, Atlanta, Georgia.
Int J Radiat Oncol Biol Phys
May 2024
Department of Radiation Oncology, New York Proton Center, New York, New York.
Support Care Cancer
October 2022
Department of Radiation Oncology, Centre François Baclesse, Caen, France.
Introduction: Despite reduction of xerostomia with intensity-modulated compared to conformal X-ray radiotherapy, radiation-induced dental complications continue to occur. Proton therapy is promising in head and neck cancers to further reduce radiation-induced side-effects, but the optimal dental management has not been defined.
Material And Methods: Dental management before proton therapy was assessed compared to intensity-modulated radiotherapy based on a bicentric experience, a literature review and illustrative cases.
Int J Part Ther
August 2021
Radiation Oncology Department, University of Washington School of Medicine, Seattle, WA, USA.
Purpose: Craniospinal irradiation (CSI) improves clinical outcomes at the cost of long-term neuroendocrine and cognitive sequelae. The purpose of this pilot study was to determine whether hypothalamic-pituitary axis (HPA) and hippocampus avoidance (HPA-HA) with intensity-modulated proton therapy (IMPT) can potentially reduce this morbidity compared with standard x-ray CSI.
Materials And Methods: We retrospectively evaluated 10 patients with medulloblastoma (mean, 7 years; range, 4-14 years).
Purpose: For most disease sites, level 1 evidence is lacking for proton beam therapy (PBT). By identifying target populations that would benefit most from PBT, prospective registries could overcome many of the challenges in clinical trial enrollment. Herein, we report clinical outcomes of patients treated with PBT for locally advanced non-small cell lung cancer (LA-NSCLC).
View Article and Find Full Text PDFBiomed Phys Eng Express
February 2022
Louisiana State University, Baton Rouge, LA, United States of America.
The objective of this study was to confirm the feasibility of three-dimensionally-printed (3D-printed), personalized whole-body anthropomorphic phantoms for radiation dose measurements in a variety of charged and uncharged particle radiation fields. We 3D-printed a personalized whole-body phantom of an adult female with a height of 154.8 cm, mass of 90.
View Article and Find Full Text PDFInt J Part Ther
May 2021
University of Pennsylvania, Philadelphia, PA, USA.
Purpose/objectives: Monte Carlo (MC) dose calculation has appeared in primary commercial treatment-planning systems and various in-house platforms. Dual-energy computed tomography (DECT) and metal artifact reduction (MAR) techniques complement MC capabilities. However, no publications have yet reported how proton therapy centers implement these new technologies, and a national survey is required to determine the feasibility of including MC and companion techniques in cooperative group clinical trials.
View Article and Find Full Text PDFInt J Part Ther
April 2021
Department of Radiation Oncology, University of Washington, Seattle, WA, USA.
Purpose: Advances in radiotherapy have improved tumor control and reduced toxicity in the management of nasopharyngeal carcinoma (NPC). Local failure remains a problem for some patients with advanced primary tumors, and toxicities are significant given the large treatment volume and tumor proximity to critical structures, even with modern photon-based radiotherapy. Proton therapy has unique dosimetric advantages, and recent technological advances now allow delivery of intensity-modulated proton therapy (IMPT), which can potentially improve the therapeutic ratio in NPC.
View Article and Find Full Text PDFAdv Radiat Oncol
July 2021
Beaumont Proton Therapy Center, Department of Radiation Oncology, Oakland University William Beaumont School of Medicine, Royal Oak, Michigan.
Purpose: Concurrent chemoradiation plays an integral role in the treatment of esophageal cancer. Proton beam radiation therapy has the potential to spare adjacent critical organs, improving toxicity profiles and potentially improving clinical outcomes.
Methods And Materials: We evaluated the REG001-09 registry for patients undergoing proton radiation therapy for esophageal cancer.
Cureus
May 2021
Department of Radiation Oncology, University of Washington, Seattle, USA.
Background and objective Fast neutron radiotherapy (NRT) is a high linear energy transfer (LET) particle therapy that offers a local control (LC) advantage over low-LET X-rays in the treatment of advanced and unresectable salivary gland malignancies. However, in tumors approximating the base of skull (BOS), target volumes may be underdosed to minimize toxicity to the central nervous system (CNS). In this setting, a proton beam boost to the underdosed part of the tumor may improve LC.
View Article and Find Full Text PDFPhys Med
December 2020
Seattle Cancer Care Alliance Proton Therapy Center, 1570 N 115th St., Seattle, WA 98133, United States; Departments of Radiation Oncology, University of Washington School of Medicine, 1959 NE Pacific St., Seattle, WA 98195, United States. Electronic address:
Purpose: This work aims to validate new 6D couch features and their implementation for seated radiotherapy in RayStation (RS) treatment planning system (TPS).
Materials And Methods: In RS TPS, new 6D couch features are (i) chair support device, (ii) patient treatment option of "Sitting: face towards the front of the chair", and (iii) patient support pitch and roll capabilities. The validation of pitch and roll was performed by comparing TPS generated DRRs with planar x-rays.
Radiat Oncol
November 2020
Beaumont Proton Therapy Center, Royal Oak, MI, USA.
Background: Recent advances in radiotherapy techniques have allowed ablative doses to be safely delivered to inoperable liver tumors. In this setting, proton beam radiotherapy (PBT) provides the means to escalate radiation dose to the target volume while sparing the uninvolved liver. This study evaluated the safety and efficacy of hypofractionated PBT for liver tumors, predominantly hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC).
View Article and Find Full Text PDFPhys Med
October 2020
Seattle Cancer Care Alliance Proton Therapy Center, 1570 N 115th St., Seattle, WA 98133, USA; Department of Radiation Oncology, University of Washington School of Medicine, 1959 NE Pacific St., Seattle, WA 98195, USA.
Purpose: This study aims to investigate the use of machine learning models for delivery error prediction in proton pencil beam scanning (PBS) delivery.
Methods: A dataset of planned and delivered PBS spot parameters was generated from a set of 20 prostate patient treatments. Planned spot parameters (spot position, MU and energy) were extracted from the treatment planning system (TPS) for each beam.
Int J Part Ther
December 2019
Department of Radiation Oncology, University of Washington Medical Center, Seattle, WA, USA.
Purpose: Proton therapy can potentially improve the therapeutic ratio over conventional radiation therapy for oropharyngeal squamous cell cancer (OPSCC) by decreasing acute and late toxicity. We report our early clinical experience with intensity-modulated proton therapy (IMPT).
Materials And Methods: We retrospectively reviewed patients with OPSCC treated with IMPT at our center.
Pract Radiat Oncol
August 2021
Department of Radiation Oncology, University of Washington School of Medicine, Seattle, Washington.
Purpose: Radiation therapy for mesothelioma remains challenging, as normal tissue toxicity limits the amount of radiation that can be safely delivered to the pleural surfaces, especially radiation dose to the contralateral lung. The physical properties of proton therapy result in better sparing of normal tissues when treating the pleura, both in the postpneumonectomy setting and the lung-intact setting. Compared with photon radiation, there are dramatic reductions in dose to the contralateral lung, heart, liver, kidneys, and stomach.
View Article and Find Full Text PDFBackground: Existing pencil beam analytical (PBA) algorithms for proton therapy treatment planning are not ideal for sites with heterogeneous tissue density and do not account for the spatial variations in proton relative biological effectiveness (vRBE). Using a commercially available Monte Carlo (MC) treatment planning system, we compared various dosimetric endpoints between proton PBA, proton MC, and photon treatment plans among patients with mediastinal lymphoma.
Methods: Eight mediastinal lymphoma patients with both free breathing (FB) and deep inspiration breath hold (DIBH) CT simulation scans were analyzed.
Int J Part Ther
April 2019
Radiation Oncology and Radiology, University of Washington School of Medicine, Seattle, WA, USA.
Purpose: Pencil beam (PB) analytical algorithms have been the standard of care for proton therapy dose calculations. The introduction of Monte Carlo (MC) algorithms may provide more robust and accurate planning and can improve therapeutic benefit. We conducted a dosimetric analysis to quantify the differences between MC and PB algorithms in the clinical setting of dose-painted nasopharyngeal cancer intensity-modulated proton radiotherapy.
View Article and Find Full Text PDFHematol Oncol Clin North Am
February 2020
Department of Radiation Oncology, Dana-Farber/Brigham and Women's Cancer Center, Harvard Medical School, 75 Francis Street, Boston, MA 02115, USA. Electronic address:
Radiation therapy plays a critical role in the management of a wide range of hematologic malignancies. The optimal radiation dose and target volume, and safe and effective ways of integrating radiation with systemic agents, vary depending on the histologic subtypes, stage at presentation, patient performance status, response to systemic therapy if given, treatment intent, and patient preferences. Limiting doses to surrounding organs without sacrificing disease control is of paramount importance.
View Article and Find Full Text PDFAdv Radiat Oncol
July 2019
Department of Radiation Oncology, Mayo Clinic, Phoenix, Arizona.
Purpose: To report the outcomes of sinonasal tumors treated with proton beam therapy (PBT) on the Proton Collaborative Group registry study.
Methods And Materials: Sixty-nine patients with sinonasal tumors underwent curative intent PBT between 2010 and 2016. Patients who received de novo irradiation (42 patients) were analyzed separately from those who received reirradiation (27 patients) (re-RT).
Radiat Oncol
June 2019
Department of Radiation Oncology, Mayo Clinic, Phoenix, AZ, 85054, USA.
Purpose: The purpose of this study is to evaluate the impact of two methods of reporting planned dose distributions on the Gamma analysis pass rates for comparison with measured 2D film dose and simulated delivered 3D dose for proton pencil beam scanning treatment of the Imaging and Radiation Oncology Core (IROC) proton lung and liver mobile phantoms.
Methods And Materials: Four-dimensional (4D) computed-tomography (CT) image sets were acquired for IROC proton lung and liver mobile phantoms, which include dosimetry inserts that contains targets, thermoluminescent dosimeters and EBT2 films for plan dose verification. 4DCT measured fixed motion magnitudes were 1.
Pract Radiat Oncol
December 2019
Department of Radiation Oncology, University of Maryland School of Medicine, Baltimore, Maryland. Electronic address:
Purpose: We sought to assess clinical outcomes and toxicities of patients with recurrent lung cancer reirradiated with proton beam therapy (PBT) who were enrolled in 2 prospective registry trials.
Methods And Materials: Seventy-nine consecutive patients were reirradiated with PBT at 8 institutions. Conventionally fractionated radiation therapy was used to treat the previous lung cancer in 68% of patients (median equivalent dose in 2 Gy fractions [EQD], 60.
Int J Radiat Oncol Biol Phys
June 2019
Department of Radiation Oncology, University of Washington School of Medicine, Seattle, Washington.
Purpose: This study examines the relationship between dose to corneal substructures and incidence of corneal toxicity within 6 months of proton beam therapy (PBT) for uveal melanoma. We aim to develop clinically meaningful dose constraints that can be used to mitigate corneal toxicity.
Methods And Materials: Ninety-two patients were treated with PBT between 2015 and 2017 and evaluated for grade 2+ (GR2+) intervention-requiring corneal toxicity in our prospectively maintained database.
Adv Radiat Oncol
August 2018
Department of Radiation Oncology, University of Washington School of Medicine, Seattle, Washington.
Purpose: We characterized both physician- and patient-reported rates of gastrointestinal (GI) toxicity in patients treated with proton beam therapy (PBT) at our institution for prostate adenocarcinoma and identified factors associated with toxicity.
Methods And Materials: We treated 192 patients with PBT between July 2013 and July 2016. Included patients had ≥1 year of follow-up.
Radiat Oncol
September 2018
Department of Radiation Oncology, University of Washington School of Medicine, 1959 NE Pacific Street, Campus, Box 356043, Seattle, WA, 98195, USA.